TELA News and Press, TELA Bio Inc. From 02/28/23

MALVERN, Pa., Feb. 28, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the pa...

MALVERN, Pa., Feb. 21, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, ...

TELA Bio ( NASDAQ: TELA ) announced a three-year dual-source agreement in the biosynthetic category with one of the Nation’s group purchasing organizations (or GPO). The agreement, which runs through January 1, 2026, offers sizable growth opportunity over the contract perio...

MALVERN, Pa., Feb. 14, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc. (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, today ann...

Summary We conclude our roundtable series with Biotech and Healthcare coverage. Three of our Marketplace contributors give their analysis and shared one top idea. Look for more roundtables and analysis this summer from our community of 180-plus Marketplace services. ~ By...

MALVERN, Pa., Jan. 09, 2023 (GLOBE NEWSWIRE) -- TELA Bio, Inc . (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative technologies that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, ...

Summary TELA recently broke out from an 18-week long sideways channel. Broad market fundamentals point to a difficult period for risk-assets into the new year. TELA shares had caught a strong bid 2 weeks ago; however, the buying momentum hasn't sustained itself to the present day. ...

MALVERN, Pa., Dec. 21, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own ...

MALVERN, Pa., Nov. 21, 2022 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’...

TELA Bio press release ( NASDAQ: TELA ): Q3 GAAP EPS of -$0.64 misses by $0.02 . Revenue of $11.2M beats by $0.33M . 2022 Financial Guidance We continue to expect full year 2022 revenue to range from $42 million to $45 million vs $42.80M consensus, refl...